Home > Keywords > Mise en page > page_accueil_3_actus

page_accueil_3_actus

Articles

  • How blood–brain barrier technology is unleashing CNS therapies
    18 March, by Emmanuelle BETTENDORF

    We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
    This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
    Click below for the full article.
    👉 (…)

  • Vect-Horus further strengthens leadership with appointment of strategy and finance executive Jérôme Berger to its Board of Directors
    3 February, by Emmanuelle BETTENDORF

    We are excited that Jerome Berger is joining our Board of Directors!
    Jerome brings vast expertise in strategy, finance, and venture capital in the technology and life sciences sectors, which will be invaluable as Vect-Horus accelerates its growth and development.
    “Jerome’s unparalleled experience in strategy, venture capital and global financing, coupled with his strong background in digital health and life sciences, will be invaluable in supporting the development of Vect-Horus as we (…)

  • Vect-Horus poursuit le renforcement son équipe de direction en nommant Carole Imbert au poste de Directrice Financière
    25 March, by Emmanuelle BETTENDORF

    We are thrilled to welcome Carole Imbert to our executive management team as our new Chief Financial Officer.
    “Her extensive background in financial strategy and investor relations will be complementary to our existing skilled team, and an invaluable asset to drive our growth and secure a strong financial position to underpin development of our vectors that facilitate targeting and delivery of therapeutics,” says @Alexandre Tokay, co-founder and CEO of Vect-Horus.
    “Carole’s leadership (…)

  • mRNA Based Therapeutics poster
    3 February, by Emmanuelle BETTENDORF

    Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
    Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

  • Vect-Horus has been honored with a prestigious European Enterprise Award
    18 March, by Emmanuelle BETTENDORF

    We are thrilled to announce that Vect-Horus has been honored with a prestigious European Enterprise Award by EU Business News! Vect-Horus is cited as one of the Pharma & Biotech Innovators of the Year 2024 ».
    These awards recognize outstanding businesses thriving across Europe. This recognition highlights our ongoing commitment to innovation in biotechnology, particularly our efforts to revolutionize drug delivery using our unique VECTrans® technology.
    A heartfelt thank you to our (…)

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

  • Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
    22 April 2024, by Emmanuelle BETTENDORF

    Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
    The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

  • Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
    30 January 2024, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that (…)

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f